⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
⏳ You're moving too fast! Cooldown active — please try again in 9 minutes.
Top story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Read full story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

Drugs.com - New Drug Applications
Wed, 31 Dec 2025
Read more

FDA Approves Yartemlea (narsoplimab-wuug) for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Drugs.com - New Drug Approvals
Wed, 24 Dec 2025
Read more

FDA Grants Accelerated Approval for Voyxact (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression

Drugs.com - New Drug Approvals
Wed, 26 Nov 2025
Read more

FDA Grants Accelerated Approval for Voyxact (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy

Drugs.com - New Drug Approvals
Wed, 26 Nov 2025
Read more

FDA Grants Full Approval to Amgen's Imdelltra (tarlatamab-dlle) in Extensive Stage Small Cell Lung Cancer

Drugs.com - New Drug Approvals
Wed, 19 Nov 2025
Read more

Eylea HD (aflibercept) Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Drugs.com - New Drug Approvals
Wed, 19 Nov 2025
Read more

FDA Grants Accelerated Approval to Hyrnuo (sevabertinib) for Non-Squamous Non-Small Cell Lung Cancer

Drugs.com - New Drug Approvals
Wed, 19 Nov 2025
Read more

FDA Grants Traditional Approval to Daratumumab and Hyaluronidase-fihj for Newly Diagnosed Light Chain Amyloidosis

Drugs.com - New Drug Approvals
Wed, 19 Nov 2025
Read more

FDA Issues Complete Response Letter for Biohaven's Vyglxia (troriluzole) New Drug Application for Spinocerebellar Ataxia

Drugs.com - New Drug Applications
Wed, 05 Nov 2025
Read more